Pharmacological Treatment of Bipolar Disorder: Japanese Expert Consensus 2025
Background: Clinical guidelines do not fully address complex treatment scenarios in bipolar disorder. We conducted an updated Japanese expert consensus survey using an innovative two-step design to distinguish broad acceptable therapeutic options from concrete regimen-level priorities across 17 clinical questions (CQs). Methods: Between October 3 and 17, 2025, 350 psychiatrists jointly certified in neuropsychopharmacology in Japan were surveyed. For each CQ, respondents selected all acceptable medications from a structured list (descriptively categorized as Tier 1 [≥65%], Tier 2 [35%–<65%], or Tier 3 [<35%]) and specified their single preferred regimen via free text. Results: A total of 159 psychiatrists responded (45.4%). In manic/hypomanic CQs, lithium, valproate, olanzapine, and aripiprazole frequently reached Tier 1; however, aripiprazole monotherapy was the most preferred regimen across all six CQs and the sole Tier 1 agent for perinatal mania. In acute depression, lithium, lurasidone, quetiapine extended-release, and lamotrigine predominated, whereas mixed-features and rapid-cycling CQs were characterized by valproate, lithium, olanzapine, and aripiprazole, with widely dispersed preferred regimens. In maintenance treatment, lithium, aripiprazole, and valproate predominated, with lithium most frequently preferred. Notably, candidate selections and preferred regimens diverged: lemborexant was consistently Tier 2 across all CQs but never ranked among the top three preferred regimens. Conclusions: The two-step design revealed a meaningful divergence between the breadth of clinically acceptable options and prioritized prescribing regimens. These findings deliver pragmatic, scenario-specific guidance that effectively bridges evidence-based recommendations and real-world clinical decision-making.
Authors
- 淳一 伊賀
- Hiroyuki Muraoka (ORCID: https://orcid.org/0000-0002-6728-5341)
- Yoshiteru Takekita (ORCID: https://orcid.org/0000-0003-2435-4033)
- Saki Hattori (ORCID: https://orcid.org/0000-0002-3156-0540)
- Ken Inada (ORCID: https://orcid.org/0000-0002-3073-4588)
- Hiromi Tagata (ORCID: https://orcid.org/0009-0005-2298-1561)
- 靖史 川又
- Hajime Baba (ORCID: https://orcid.org/0000-0001-9678-8776)
- Akira Nishi (ORCID: https://orcid.org/0000-0003-2146-7227)
- Hitoshi Sakurai (ORCID: https://orcid.org/0000-0002-5399-7946)
- あすか 香月
- 越智紳一郎
- Kyosuke Sawada
- Norio Yasui‐Furukori (ORCID: https://orcid.org/0000-0002-4414-3770)
- Toshiaki Kikuchi (ORCID: https://orcid.org/0000-0003-1025-8796)
- Masaki Kato
- Hideaki Tani
- Koichiro Watanabe
Institutions
- Kansai Medical University (JP)
- Toho University (JP)
- Kyorin University (JP)
- Keio University (JP)
- Juntendo University (JP)
- Ehime University (JP)
- Kitasato University (JP)
- Dokkyo Medical University (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-20
- DOI
- https://doi.org/10.21203/rs.3.rs-11673756/v1
- Primary Topic
- Bipolar Disorder and Treatment
- Type
- preprint
Funders
- Japanese Society of Clinical Neuropsychopharmacology